Our results demonstrated for the first time that Pg, a classical thiazolidinedione drug for type 2 diabetes treatments, can be used to efficiently promote mitochondrial biogenesis of hMSC by activating the PGC-1α/NRF1/TFAM pathway. Here, PPARGC1A is linked to type 2 diabetes mellitus.